RO5166017

Pharmacology

Pharmacodynamics

Actions

RO5166017 is a partial agonist or near-full agonist of the TAAR1 depending on the species examined. Its values are 3.3 to 8.0nM for the mouse TAAR1 (mTAAR1), 14nM for the rat TAAR1 (rTAAR1), 97nM for the cynomolgus monkey TAAR1, and 55nM for the human TAAR1. Its values are 65 to 72% for the mTAAR1, 90% for the rTAAR1, 81% for the cynomolgus monkey TAAR1, and 95% for the hTAAR1. RO5166017 is selective for the TAAR1 over a large array of other targets.

Effects

RO5166017 has been found to inhibit the firing rates of ventral tegmental area (VTA) dopaminergic neurons and dorsal raphe nucleus (DRN) serotonergic neurons in mouse brain slices ex vivo. Conversely, it had no effect on the firing rates of locus coeruleus (LC) noradrenergic neurons, an area where TAAR1 is not expressed. The effects of RO5166017 on monoaminergic neuron firing frequencies were absent in TAAR1 knockout mice and could be reversed by the TAAR1 antagonist RTI-7470-44, indicating that they were mediated by TAAR1 activation. Similar effects have been observed with the TAAR1 full agonist p-tyramine. Likewise, RO5166017 inhibited electrically evoked dopamine release in dorsal striatum (DStr) and nucleus accumbens (NAc) mouse brain slices ex vivo. Inhibition of NAc dopamine overflow by RO5166017 could be reversed by the TAAR1 antagonist EPPTB. Neither RO5166017 nor EPPTB had any effect on measures of dopamine reuptake or clearance (tau and half-life) in dopaminergic brain slices ex vivo.

Previous in-vitro studies found that TAAR1 could activate several signaling cascades including PKA, PKC, ERK1/2, and CREB. However, RO5166017 did not affect these signaling pathways, nor GSK3β, in rats in vivo, and instead selectively and TAAR1-dependently inhibited CaMKIIα activity in the NAc.

In animal studies, RO5166017 has little or no effect on locomotor activity itself. In contrast to psychostimulants like amphetamine and cocaine, it does not show stimulant-like or rewarding effects across a broad dose range. The drug dose-dependently suppresses cocaine-induced hyperlocomotion and stereotypies. Likewise, it suppresses hyperlocomotion induced by the NMDA receptor antagonist L-687,414. In dopamine transporter (DAT) knockout mice, which show spontaneous hyperactivity in novel environments, RO5166017 suppresses hyperlocomotion. These effects of RO5166017 are similar to those of antipsychotics like haloperidol and olanzapine. They are absent in TAAR1 knockout mice, indicating that they are mediated by the TAAR1. These findings indicate that RO5166017 has antipsychotic-like effects.

RO5166017 has been found to inhibit expression, though not reconsolidation or retention, of cocaine-induced conditioned place preference (CPP) in mice. Systemic administration or microinjection of RO5166017 into various brain regions has been found to inhibit other cocaine-induced relapse-like behaviors in rodents as well. As with cocaine, RO5166017 has been found to inhibit nicotine-induced dopamine release in the NAc and to reduce nicotine intake and relapse-like behaviors.

RO5166017 has been shown shown to prevent stress-induced hyperthermia in rodents. It has shown robust aversive effects in rodents, similarly to other TAAR1 agonists like RO5256390 and RO5263397. RO5166017 has shown anxiolytic-like effects in mice. It has been found to produce anti-impulsivity-like effects in mice. The drug has been found to augment 6-hydroxydopamine (6-OHDA)-induced dopaminergic neurodegeneration in mice and to counteract levodopa-induced contralateral rotations and dyskinesia. RO5166017 has shown anti-post-traumatic stress disorder (PTSD)-like effects in rodents.

Pharmacokinetics

RO5166017 has shown favorable pharmacokinetic properties for in vivo use.

History

RO5166017 was first described in the scientific literature by 2011. It was the first selective TAAR1 agonist to be discovered.

References

References

1. (May 2013). "A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight". Mol Psychiatry.
2. (May 2011). "TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity". Proc Natl Acad Sci U S A.
3. (April 2022). "Identification of a Potent Human Trace Amine-Associated Receptor 1 Antagonist". ACS Chem Neurosci.
4. (December 2021). "Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies". Int J Mol Sci.
5. (August 2015). "Trace amine-associated receptor 1: A promising target for the treatment of psychostimulant addiction". Eur J Pharmacol.
6. (March 2008). "Trace amine-associated receptor 1 modulates dopaminergic activity". J Pharmacol Exp Ther.
7. (November 2009). "The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system". Proc Natl Acad Sci U S A.
8. (2016). "Trace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical Implications". Front Neurosci.
9. (2017). "The Case for TAAR1 as a Modulator of Central Nervous System Function". Front Pharmacol.
10. (June 2014). "Taar1-mediated modulation of presynaptic dopaminergic neurotransmission: role of D2 dopamine autoreceptors". Neuropharmacology.
11. (2012). "Emerging Targets for Drug Addiction Treatment". Nova Science Publishers.
12. (2018). "TAAR1 in Addiction: Looking Beyond the Tip of the Iceberg". Front Pharmacol.
13. (July 2016). "Effects of Trace Amine-associated Receptor 1 Agonists on the Expression, Reconsolidation, and Extinction of Cocaine Reward Memory". Int J Neuropsychopharmacol.
14. (January 2017). "Role of TAAR1 within the Subregions of the Mesocorticolimbic Dopaminergic System in Cocaine-Seeking Behavior". J Neurosci.
15. (April 2022). "TAAR1 regulates drug-induced reinstatement of cocaine-seeking via negatively modulating CaMKIIα activity in the NAc". Mol Psychiatry.
16. (November 2018). "Role of trace amine-associated receptor 1 in nicotine's behavioral and neurochemical effects". Neuropsychopharmacology.
17. (September 2023). "Robust aversive effects of trace amine-associated receptor 1 activation in mice". Neuropsychopharmacology.
18. (October 2022). "Selective TAAR1 agonists induce conditioned taste aversion". Psychopharmacology (Berl).
19. (March 2020). "TAAR1 and Psychostimulant Addiction". Cell Mol Neurobiol.
20. (August 2015). "TAAR1 Modulates Cortical Glutamate NMDA Receptor Function". Neuropsychopharmacology.
21. (December 2017). "Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges". Pharmacol Ther.
22. (October 2015). "Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission". J Neurosci.
23. (October 2024). "Activation of trace amine-associated receptor 1 ameliorates PTSD-like symptoms". Biochem Pharmacol.
24. (December 2021). "Potential of Ligands for Trace Amine-Associated Receptor 1 (TAAR1) in the Management of Substance Use Disorders". CNS Drugs.
25. (April 2013). "Insights into the structure and pharmacology of the human trace amine-associated receptor 1 (hTAAR1): homology modelling and docking studies". Chem Biol Drug Des.